Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $10. The average 1-year stock price forecast is 16.01% higher than the current stock price, while the lowest is $6.00 (-30.39%) and the highest is $14 (+62.41%).

Price Target: $10 (+16.01%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$6.00	$10	$10	$14
Change	-30.39%	+16.01%	+16.01%	+62.41%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	6	6	6	6	5	5
Buy	2	2	2	2	2	2
Hold	3	3	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	10	10	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Nicholas Lorusso TD Cowen	TD Cowen	Buy Reiterates $7 → $10	Buy	Reiterates	$7 → $10	+16.01%	Aug 25, 2026
David Dai UBS	UBS	Hold Reiterates $4 → $7	Hold	Reiterates	$4 → $7	-18.79%	Aug 20, 2026
Salim Syed Mizuho Securities	Mizuho Securities	Buy Maintains $10 → $11	Buy	Maintains	$10 → $11	+27.61%	Aug 17, 2026
Colleen M. Kusy Robert W. Baird	Robert W. Baird	Hold Maintains $4 → $6	Hold	Maintains	$4 → $6	-30.39%	Aug 7, 2026
Reni Benjamin Citizens JMP	Citizens JMP	Buy Maintains $5 → $8	Buy	Maintains	$5 → $8	-7.19%	Aug 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

401.54M

from 263.50M

52.39%

from 263.50M

Revenue Next Year

557.44M

from 401.54M

38.82%

from 401.54M

EPS This Year

-0.50

from -1.09

EPS Next Year

-0.29

from -0.50

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	1.19M	164.07M	263.50M	401.54M
Revenue Growth	-	-	-	13,698.99%	60.60%	52.39%
Operating Income	-342.70M	-398.88M	-460.56M	-395.28M	-398.21M	-222.86M
Net Income	-342.25M	-395.89M	-444.04M	-372.18M	-390.98M	-212.72M
EPS	-	-	-	-	-1.09	-0.50
Free Cash Flow	-129.35M	-173.54M	-211.47M	-198.76M	-162.42M	-168.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	422.0M
Avg	401.5M
Low	375.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	60.2%
Avg	52.4%
Low	42.3%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.45
Avg	-0.50
Low	-0.58

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-